体外研究 (In Vitro) |
Escin Ia (2.5-10 μM;24 h) 以浓度依赖的方式抑制 MDA-MB-231 细胞的侵袭,其中 10 μM 浓度下的抑制作用最强 (76.23%)。 Escin Ia (2.5-10 μM; 24 h) 可调控 MDA-MB-231 细胞中LOXL2、E-钙粘蛋白 (E-cadherin)和MMP9的 mRNA 表达,其中LOXL2表达下调与E-钙粘蛋白 (E-cadherin)表达上调为其显著作用。 Escin Ia (2.5-10 μM; 6-24 h, unspecified intervals) 可通过调控上皮间质转化 (EMT) 标志物及转录因子,抑制 MDA-MB-231 细胞中的上皮间质转化 (EMT) 过程。 Escin Ia (2.5-10 μM;6-24 h, unspecified intervals) 可通过使 EMT 标志物表达恢复正常,逆转经 TNF−α/TGF−β刺激的 MCF-7 细胞中的 EMT 进程。 Escin Ia (2.5-10 μM;6-24 h,unspecified intervals) 可下调 MDA-MB-231 细胞中 LOXL2 的表达,并可消除经 TNF-α/TGF-β 刺激或转染 LOXL2 的 MCF-7 细胞中诱导产生的 LOXL2 表达。 Escin Ia (2.5-10 μM; unspecified intervals) 可通过下调 LOXL2 表达并使 EMT 标记物恢复正常,来抑制转染 LOXL2 的 MCF-7 细胞中的 EMT 进程。 Escin Ia (2.5-10 μM; unspecified intervals) 可通过下调 LOXL2 (不影响 HIF-1α) 并使 EMT 标志物恢复正常,从而抑制低氧诱导的 MCF-7 细胞中的 EMT 进程。
Cell Invasion Assay
| Cell Line: |
MDA-MB-231 |
| Concentration: |
5 μM; 2.5-10 μM |
| Incubation Time: |
24 h |
| Result: |
Inhibited MDA-MB-231 cell invasion by 68.92% at 5 μM (stronger than other escin analogs); inhibited invasion by 39.46% at 2.5 μM, 64.22% at 5 μM, and 76.23% at 10 μM. |
Real Time qPCR
| Cell Line: |
MDA-MB-231 |
| Concentration: |
2.5-10 μM |
| Incubation Time: |
24 h |
| Result: |
Down-regulated LOXL2 mRNA expression and up-regulated E-cadherin mRNA expression; moderately down-regulated MMP9 mRNA expression at 10 μM; exerted slight effects on BRMS1, Keratin19, Orai1, Stim1, TGF-β, and VEGF mRNAs. |
|
体内研究 (In Vivo) |
Escin Ia (2-4 mg/kg; i.p.; three times per week; five weeks) 通过下调 LOXL2 抑制 MDA-MB-231 异种移植小鼠的 TNBC 转移和 EMT,且 4 mg/kg 剂量的疗效优于 2 mg/kg。 Escin Ia (50-200 mg/kg; p.o.) 可剂量依赖性地抑制醋酸诱导的Mus musculus血管通透性,在 200 mg/kg 剂量下的抑制率为 43.6%。 Escin Ia (25-200 mg/kg; p.o.) 可抑制 compound 48/80 诱导的小鼠搔抓行为,在 200 mg/kg 剂量下的抑制率达 42.4%,具有统计学显著性。 Escin Ia (200 mg/kg; p.o.) 可显著抑制角叉菜胶诱导的大鼠爪水肿早期阶段 (1 hour)。 Escin Ia (25-200 mg/kg; p.o.) 可呈剂量依赖性抑制大鼠体内组胺诱导的血管通透性 (在 50-200 mg/kg 剂量下具有显著性),但不抑制 5-羟色胺诱导的血管通透性。 Escin IA (10-50 mg/kg; p.o.; single dose 1 hour before ethanol administration) 可通过涉及辣椒素敏感传入神经元、内源性一氧化氮和前列腺素的机制,强效保护大鼠免受乙醇诱导的胃黏膜损伤,且在有效剂量下无胃酸分泌抑制活性。 Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃保护作用依赖于辣椒素敏感的传入神经元。 Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 其在大鼠体内的胃保护作用依赖于内源性前列腺素。 Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 的胃黏膜保护作用依赖于大鼠体内的内源性一氧化氮。 Escin IA (10 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃黏膜保护作用不依赖内源性巯基。 Escin IA (10-20 mg/kg; p.o.; single dose 1 hour before ethanol administration) 对大鼠的胃保护作用依赖于交感神经系统。
| Animal Model: |
athymic nude mice (female, 4-6 week-old) |
| Dosage: |
2 mg/kg; 4 mg/kg |
| Administration: |
i.p.; three times per week; five weeks |
| Result: |
Down-regulated LOXL2, vimentin, α-SMA, Snail, Slug, Zeb1, Zeb2, and Twist, and up-regulated E-cadherin at protein and mRNA levels in breast tumors (4 mg/kg); showed little effect on HIF-1α expression in breast tumors (2 mg/kg, 4 mg/kg) |
| Animal Model: |
ddY mice (male, 27-30 g, acetic acid-induced vascular permeability model) |
| Dosage: |
50, 100, 200 mg/kg |
| Administration: |
p.o. |
| Result: |
Inhibited acetic acid-induced vascular permeability with 12.1% inhibition at 50 mg/kg, 30.6% inhibition at 100 mg/kg, and 43.6% inhibition at 200 mg/kg. |
| Animal Model: |
ddY mice (male, 26-29 g, compound 48/80-induced scratching model) |
| Dosage: |
25, 50, 100, 200 mg/kg |
| Administration: |
p.o. |
| Result: |
Inhibited compound 48/80-induced scratching with 16.8% inhibition at 25 mg/kg, 32.4% inhibition at 50 mg/kg, 31.5% inhibition at 100 mg/kg, and 42.4% inhibition at 200 mg/kg (significant at 200 mg/kg). |
| Animal Model: |
Wistar rats (male, 140-160 g, carrageenin-induced hind paw edema model) |
| Dosage: |
200 mg/kg |
| Administration: |
p.o. |
| Result: |
Significantly inhibited carrageenin-induced hind paw swelling at 1 hour but showed no effect at 3-5 hours. |
| Animal Model: |
Wistar rats (male, 140-150 g, histamine/serotonin-induced vascular permeability model) |
| Dosage: |
25, 50, 100, 200 mg/kg |
| Administration: |
p.o. |
| Result: |
Inhibited histamine-induced vascular permeability with significant effects at 50 mg/kg (28.4 μg/site dye leakage), 100 mg/kg (28.5 μg/site), and 200 mg/kg (19.4 μg/site); did not significantly inhibit serotonin-induced vascular permeability at any dose. |
| Animal Model: |
Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; ethanol-induced gastric mucosal lesions) |
| Dosage: |
10, 20, 50 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Dose-dependently reduced ethanol-induced gastric lesion scores; showed potent protective effect at 10-50 mg/kg. Did not decrease gastric secretion (volume, acid output, pepsin output) in pylorus-ligated rats at 10 and 20 mg/kg. Had gastroprotective effect attenuated by pretreatment with capsaicin, indomethacin, or L-NAME at 10 mg/kg. Had gastroprotective effect not attenuated by pretreatment with N-ethylmaleimide at 10 mg/kg. Showed marked attenuation of gastroprotective effect in streptozotocin-induced diabetic rats at 10 and 20 mg/kg. |
| Animal Model: |
Sprague-Dawley (male, 180-200 g for capsaicin pretreatment; 250 g for other pretreatments, fasted 24-26 hours prior to experiments; capsaicin-pretreated, ethanol-induced gastric mucosal lesions) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Showed gastroprotective effect against ethanol-induced lesions markedly attenuated by capsaicin pretreatment. |
| Animal Model: |
Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; indomethacin-pretreated, ethanol-induced gastric mucosal lesions) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Showed gastroprotective effect against ethanol-induced lesions partly reduced by indomethacin pretreatment. |
| Animal Model: |
Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; L-NAME-pretreated, ethanol-induced gastric mucosal lesions) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Showed gastroprotective effect against ethanol-induced lesions partly reduced by L-NAME pretreatment. |
| Animal Model: |
Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; N-ethylmaleimide-pretreated, ethanol-induced gastric mucosal lesions) |
| Dosage: |
10 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Showed gastroprotective effect against ethanol-induced lesions not attenuated by N-ethylmaleimide pretreatment. |
| Animal Model: |
Sprague-Dawley (male, 250 g, fasted 24-26 hours prior to experiments; streptozotocin-induced diabetic, ethanol-induced gastric mucosal lesions) |
| Dosage: |
10, 20 mg/kg |
| Administration: |
p.o.; single dose 1 hour before ethanol administration |
| Result: |
Showed marked attenuation of gastroprotective effect against ethanol-induced lesions in streptozotocin-induced diabetic rats at 10 and 20 mg/kg. |
|